Adalimumab News and Research

RSS
Adalimumab is an injectable prescription drug used to treat diseases of the immune system; it is marketed by Abbot as Humira. It is one of three drugs that work by inhibiting the potent inflammatory molecule tumor necrosis factor-alpha (TNF-alpha); the others are etanercept (Enbrel) and infliximab (Remicade). Like etanercept and infliximab, adalimumab is a large protein molecule made with recombinant DNA technology. Adalimumab is a monoclonal antibody of the IgG1 subtype that has been "humanized", meaning that all of its components are derived from human molecules.
IONTAS founder and pioneer in phage display technology attends Nobel Prize Award Ceremony

IONTAS founder and pioneer in phage display technology attends Nobel Prize Award Ceremony

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

Toxic effects of drugs in the lungs 'more widespread than thought'

Toxic effects of drugs in the lungs 'more widespread than thought'

Study offers new hope for people with disabling Dupuytren's disease

Study offers new hope for people with disabling Dupuytren's disease

Study: Psoriasis patients taking Humira show no change in aortic inflammation

Study: Psoriasis patients taking Humira show no change in aortic inflammation